Results 241 to 250 of about 11,453 (281)
Genetic Confirmation of Clonal Spread of <i>Candida auris</i> from Southern to Northern Nevada. [PDF]
J Fungi (Basel)Resong PJ +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2004
Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant strains.
David M Murdoch, Greg L. Plosker
+8 more sources
Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant strains.
David M Murdoch, Greg L. Plosker
+8 more sources
Anidulafungin, a New Echinocandin [PDF]
Drugs, 2009 Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungicidal activity against a wide range of Candida species, including C. glabrata and C. krusei. Anidulafungin is also active in vitro against moulds belonging to the genus Aspergillus and some dematiaceous genera.
G. Morace +3 more
openaire +7 more sources
Hospital Pharmacy, 2006
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Terri Levien +2 more
openaire +2 more sources
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Terri Levien +2 more
openaire +2 more sources
Anidulafungin: advantage for the newcomer?
Expert Review of Clinical Pharmacology, 2008Anidulafungin is the most recently approved compound of the echinocandin antifungal class. Its mode of action is the noncompetitive inhibition of β-(1,3)-D-glucan synthesis. Potent fungicidal activity has been demonstrated against many Candida spp., including non-albicansCandida spp.
Fedja Farowski +3 more
openaire +3 more sources